Monte Rosa Therapeutics stock: MRT-8102 shows gout activity in rabbits

Published on 11/12/2026 at 03:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Monte Rosa Therapeutics stock is in focus after preclinical MRT-8102 findings in gout. A Phase 2 trial is expected to start this quarter.

Clinical milestones remain ahead

MRT-8102 reduced inflammatory activity in human experimental systems and a rabbit model of gouty arthritis.
Monte Rosa expects to begin the GEMINI-1 Phase 2 study in gout during the fourth quarter of 2026.
Initial GEMINI-1 results are expected in the second half of 2027, leaving clinical validation as the next major test.

GLUE, US61225M1027, Illustration mit AI erstellt.

Monte Rosa Therapeutics presented preclinical findings for its gout candidate MRT-8102 on Monday, November 9, at ACR Convergence 2026 in Orlando. The company said the NEK7-directed molecular glue degrader inhibited NLRP3 inflammasome activity in human experimental systems and reduced inflammation in a rabbit model of gouty arthritis. The findings were reported by GlobeNewswire.

Preclinical signal precedes patient testing

MRT-8102 reduced caspase-1 activity in human macrophages stimulated with monosodium urate or calcium pyrophosphate dihydrate crystals. It also suppressed interleukin-1 beta release in stimulated whole blood from donors with and without gout.

In the rabbit model, oral treatment reduced joint swelling and improved musculoskeletal ultrasound scores compared with vehicle controls. Monte Rosa also reported target engagement through NEK7 degradation in rabbit spleens and lower synovial-fluid C-reactive protein. These are preclinical findings, so their relevance to patients will depend on the upcoming clinical program.

GEMINI-1 sets the next catalyst

Monte Rosa expects to initiate GEMINI-1, a Phase 2 study in patients with gout, in the fourth quarter of 2026. The trial is designed to evaluate prevention of recurrent flares after acute flare management, with initial results expected in the second half of 2027.

The company is also developing MRT-8102 for other diseases linked to the NEK7 and NLRP3 pathway, including atherosclerotic cardiovascular disease and hidradenitis suppurativa. Its November 9 release said the compound had reduced key pathogenic drivers of atherosclerotic cardiovascular disease in the Phase 1 GFORCE-1 study and had shown treatment-emergent adverse-event rates comparable to placebo.

Monte Rosa's platform and pipeline

According to Monte Rosa's investor relations profile, the Boston-headquartered clinical-stage biotechnology company develops molecular glue degrader medicines for oncology, autoimmune, inflammatory, cardiovascular and cardiometabolic diseases. Its QuEEN platform combines molecular glue libraries with proteomics, structural biology, computational chemistry and artificial intelligence to identify drug candidates. Research operations are based in Boston and Basel, Switzerland.